Last reviewed · How we verify

Recombinant Human Papillomavirus Nonavalent Vaccine — Competitive Intelligence Brief

Recombinant Human Papillomavirus Nonavalent Vaccine (Recombinant Human Papillomavirus Nonavalent Vaccine) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Recombinant vaccine. Area: Oncology / Immunology.

marketed Recombinant vaccine Human papillomavirus (HPV) types 6, 11, 16, 18, 31, 33, 45, 52, 58 Oncology / Immunology Biologic Live · refreshed every 30 min

Target snapshot

Recombinant Human Papillomavirus Nonavalent Vaccine (Recombinant Human Papillomavirus Nonavalent Vaccine) — National Cancer Institute (NCI). A nonavalent vaccine that stimulates the immune system to produce antibodies against nine types of human papillomavirus (HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58) to prevent HPV-related cancers and diseases.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Recombinant Human Papillomavirus Nonavalent Vaccine TARGET Recombinant Human Papillomavirus Nonavalent Vaccine National Cancer Institute (NCI) marketed Recombinant vaccine Human papillomavirus (HPV) types 6, 11, 16, 18, 31, 33, 45, 52, 58
EngerixTM-B EngerixTM-B GlaxoSmithKline marketed Recombinant vaccine Hepatitis B surface antigen (HBsAg)
Engerix B Engerix B Crucell Holland BV marketed Recombinant vaccine Hepatitis B surface antigen (HBsAg)
Engerix-B vaccine Engerix-B vaccine GlaxoSmithKline marketed Recombinant vaccine Hepatitis B surface antigen (HBsAg)
EngerixB, GlaxoSmithKline Vaccines EngerixB, GlaxoSmithKline Vaccines University of British Columbia marketed Recombinant vaccine Hepatitis B surface antigen (HBsAg)
HPV9v HPV9v Fundacion SEIMC-GESIDA marketed Recombinant vaccine Human papillomavirus (HPV) types 6, 11, 16, 18, 31, 33, 45, 52, 58
RECOMBIVAX HB™ RECOMBIVAX HB™ Merck Sharp & Dohme LLC marketed Recombinant vaccine Hepatitis B surface antigen (HBsAg)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Recombinant vaccine class)

  1. GlaxoSmithKline · 5 drugs in this class
  2. Merck Sharp & Dohme LLC · 3 drugs in this class
  3. Crucell Holland BV · 2 drugs in this class
  4. Shanghai Institute Of Biological Products · 2 drugs in this class
  5. ANRS, Emerging Infectious Diseases · 1 drug in this class
  6. University of British Columbia · 1 drug in this class
  7. Fundacion SEIMC-GESIDA · 1 drug in this class
  8. National Cancer Institute (NCI) · 1 drug in this class
  9. Pontificia Universidad Catolica de Chile · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Recombinant Human Papillomavirus Nonavalent Vaccine — Competitive Intelligence Brief. https://druglandscape.com/ci/recombinant-human-papillomavirus-nonavalent-vaccine. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators: